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I read Nagel et al. with interest (Nagel et al., 2015). In theory, the potential to modify cognitive
function in Huntington’s disease (HD) with electrical stimulation or specifically Deep Brain Stim-
ulation (DBS) is exciting. HD is a devastating and terminal disease in need of better treatments,
both symptomatic and neuroprotective. Cognitive dysfunction itself is becoming more recognized
as a severely disabling aspect of the disease as well (Paulsen and Long, 2014). Nagel et al. out-
line an intriguing argument for pursuing the globus pallidus externa as a DBS target for cognitive
improvement while also acknowledging that the current evidence is based on a small number of
animal models and very limited human (n = 2) experience.
In actuality, the practical nature of pursing DBS for the treatment of cognition in HD is more
complicated. The ethics of pursuing DBS for new indications is a hotly debated topic (Unter-
rainer and Oduncu, 2015). We still do not yet fully understand the mechanism of DBS in treat-
ing disorders where its efficacy is established. Trialing it for other neurologic conditions without
sound rational can be unnecessarily dangerous and not in the best interest of those we are try-
ing to treat. While DBS was relatively free of complications in limited trials for HD chorea, it
is not a benign procedure. It is a brain surgery with known irreversible surgical complications
including infection, stroke, intracranial bleeding and even death (Bronstein et al., 2011). Some
authors cite complication rates in Parkinson’s disease as high as 10% for hemorrhage, 2% for
stroke, 15% for infection and death rates up to 4.5% (Bronstein et al., 2011). Hardware com-
plications requiring repeat surgery also occur. Finally, cognition and behavior have also been
known to be negatively impacted after DBS surgery, albeit more often cited in the subthala-
mic target for Parkinson’s disease. Still, there are accounts of cognitive decline and even mania
after pallidal DBS as well (Miyawaki et al., 2000; Rothlind et al., 2014). Considering these known
potential neuropsychiatric complications, trials of DBS for HD would need to proceed very cau-
tiously given the high incidence of pre-existing cognitive dysfunction and increased risk for
suicide.
Lastly, I would caution against making any statements alluding to slowing disease progression or
neuroprotection given the current data, especially to perspective future participants in any DBS tri-
als. This is too premature. This is indeed a desperate population and the ability to identify subjects
early in the prodromal stage of the disease increases the potential for inappropriate and improper
recruitment to any future trials. Any research using DBS in this population needs to be done slowly
Tolleson Commentary on DBS in Huntington’s
with the highest ethical standards and rigorous consenting pro-
tocols. Personally, while I commonly recommend DBS for my
patients for treatment of currently approved indications and
participate in a high volume of surgeries, I am still holding out
hope for a medicinal, neuroprotective therapy that would have
reversible adverse effects and not carry the risk of a brain surgery.
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